Healthcare
Live Price
Offline$4.12
-1.20% today
1Y Change
-11.26%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Verastem, Inc. (VSTM) is a Healthcare stock with a market cap of $410.00M and listed on NASDAQ. The stock last traded around $4.12 and down 11.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +209.1%, EPS growth of +17.5%, a dividend yield of 0.0%. What stands out right now is revenue +209.1%, EPS +17.5%, free cash flow -31.2% with operating margin -550.3% and ROIC -94.5%. Valuation already assumes a fairly strong business story at price/sales 13.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VSTM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VSTM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VSTM Max Drawdown
-66.39%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VSTM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.1M
-20.9% YoY
FY Net Income
-$71.2M
+3.5% YoY
Free Cash Flow
-$53.7M
+15.7% YoY
Revenue Growth
+209.1%
EPS Growth
+17.5%
Gross Margin
83.8%
Net Margin
-677.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 31M | 10M | 0 | 3M | 2M |
| Gross Profit | 26M | 10M | 0 | 3M | 2M |
| Operating Income | -170M | -115M | -92M | -73M | -61M |
| EBITDA | -170M | -126M | -83M | -72M | -61M |
| Net Income | -209M | -131M | -87M | -74M | -71M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 205M | 89M | 78M | 75M | 21M |
| Total Assets | 246M | 102M | 150M | 95M | 109M |
| Total Liabilities | 189M | 130M | 92M | 48M | 21M |
| Shareholder Equity | 57M | -29M | 57M | 47M | 88M |
| Total Debt | 77M | 42M | 42M | 27M | 3M |
| Net Debt | -128M | -47M | -36M | -48M | -18M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
54M
+16.0% YoY
Capital Expenditures
196K
Free Cash Flow
54M
+15.7% YoY
Key ratios
Gross Margin
83.8%
Operating Margin
-550.3%
Net Margin
-677.6%
ROE
-1849.9%
Debt / Equity
1.52x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.